Follicular Lymphoma Clinical Trials in Durham, North Carolina

4 studies are recruiting for follicular lymphoma in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307), Durham, North Carolina
    Locations
    25 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT07634471 on ClinicalTrials.gov

  2. Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

    This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Duke Univerisity, Durham, North Carolina
    Locations
    4 in total
    Run by
    Newave Pharmaceutical Inc

    See if you can join NCT04775745 on ClinicalTrials.gov

  3. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Duke University, Durham, North Carolina
    Locations
    36 in total
    Run by
    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

  4. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Duke University, Durham, North Carolina
    Locations
    13 in total
    Run by
    Carna Biosciences, Inc.

    See if you can join NCT05602363 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.